This study reports a synergistic drug combination by targeting FGFR1 and PLK1 and identifies autophagy as a protective mechanism that limits the efficacy of FGFR1/PLK1 inhibitor therapy in KRAS‐mutant lung cancer, suggesting a novel strategy to treat the daunting disease. Here, KRAS is linked to lung carcinoma.